4/A//SEC Filing
Orexigen Therapeutics, Inc. 4/A
Accession 0001181431-13-046848
CIK 0001382911operating
Filed
Aug 27, 8:00 PM ET
Accepted
Aug 28, 9:03 PM ET
Size
6.2 KB
Accession
0001181431-13-046848
Insider Transaction Report
Form 4/AAmended
Endicott David J.
Director
Transactions
- Award
Stock Option (right to buy)
2013-06-05+18,126→ 18,126 totalExercise: $6.09Exp: 2023-06-04→ Common Stock (18,126 underlying)
Footnotes (3)
- [F1]This amended report is being filed to correct a clerical error in the reporting person's original report. The number of shares subject to the stock option was originally reported as 35,000 shares, but has been corrected to 18,126 shares, an amount pro-rated based on the reporting person's period of service as a director.
- [F2]1/12th of the original number of shares of stock subject to the Option (rounded down to the next whole number of shares) shall vest on the same day of each one-month period of Reporting Person's service as an Director following the Vesting Commencement Date, such that the Option shall be 100% vested on the first (1st) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuing service on the board of directors through such dates. The shares subject to the Option shall vest on an accelerated basis in the event of the occurrence of a Change in Control as described in Section 3.1(c) of the Stock Option Agreement.
- [F3]Not applicable.
Documents
Issuer
Orexigen Therapeutics, Inc.
CIK 0001382911
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001382911
Filing Metadata
- Form type
- 4/A
- Filed
- Aug 27, 8:00 PM ET
- Accepted
- Aug 28, 9:03 PM ET
- Size
- 6.2 KB